A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis
Latest Information Update: 18 Jun 2025
At a glance
- Drugs KBL 697 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors KoBioLabs
Most Recent Events
- 18 Jun 2025 New trial record